Back

Echocardiographic variables may improve baseline risk prediction of cancer therapy related cardiac dysfunction

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: predicting adverse effects and prognosis Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lorcan Ruane

Mater Private Hospital Brisbane, Brisbane (Australia)

9 More presentations in this session

Presentation thumbnail
Adverse Myocardial and vascular side effects of Immune Checkpoint Inhibitors: a prospective multimodal cardiovascular assessment (AMICI study)
Doctor M. Mirabel (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in acute coronary syndrome patients with cancer: a statewide population-linkage study
Doctor C. Yu (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The CTOX-Score, a clinical risk prediction tool for cardiovascular toxicity secondary to cancer therapies
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Fibroblast activation in cardio-oncology
Doctor K. Loganath (Southampton, GB)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?
Doctor T. Georgopoulou (Heraklion, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: predicting adverse effects and prognosis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
A study to assess the ability of the HFA-ICOS risk stratification tool to predict cancer therapy-related cardiac dysfunction for patients receiving anthracycline chemotherapy.
thumbnail
Congress Presentation
Cardiotoxicity risk assessment using HFA-ICOS score: a cross-sectional analysis of patients with breast cancer undergoing chemotherapy or anti-HER2 therapies in a tertiary care center

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources